Cancer Immunology, Immunotherapy

, Volume 68, Issue 11, pp 1881–1889 | Cite as

Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy

  • Timothy T. SpearEmail author
  • Brian D. Evavold
  • Brian M. Baker
  • Michael I. Nishimura
Focussed Research Review


Adoptive cell transfer (ACT) using T cell receptor (TCR) gene-modified T cells is an exciting and rapidly evolving field. Numerous preclinical and clinical studies have demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T cells to treat cancer and viral infections. Although evidence suggests their use can be effective, to what extent and how to improve these therapeutics are still matters of investigation. As TCR affinity has been generally accepted as the central role in defining T cell specificity and sensitivity, selection for and generation of high affinity TCRs has remained a fundamental approach to design more potent T cells. However, traditional methods for affinity-enhancement by random mutagenesis can induce undesirable cross-reactivity causing on- and off-target adverse events, generate exhausted effectors by overstimulation, and ignore other kinetic and cellular parameters that have been shown to impact antigen specificity. In this Focussed Research Review, we comment on the preclinical and clinical potential of TCR gene-modified T cells, summarize our contributions challenging the role TCR affinity plays in antigen recognition, and explore how structure-guided design can be used to manipulate antigen specificity and TCR cross-reactivity to improve the safety and efficacy of TCR gene-modified T cells used in ACT.


T cell T cell receptor (TCR) TCR affinity TCR cross-reactivity Adoptive cell transfer PIVAC 18 



Adoptive cell transfer


Altered peptide ligand


Hepatocellular carcinoma


Hepatitis C virus


Peripheral blood lymphocyte


Peptide-major histocompatibility complex


T cell receptor


Author contributions

TT Spear, BD Evavold, BMB, and MIN designed the research, performed experiments, and analyzed the data summarized in the Focussed Research Review as well as wrote and critically revised the manuscript.


The authors’ original work described and summarized in this Focussed Research Review was funded by the National Cancer Institute (Grants F30 CA180731 to Spear; P01 CA154779 to Nishimura) and the National Institute of Allergy and Infectious Disease (Grants R01 AI129543 to Baker & Nishimura; R01 AI096879 to Evavold).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Spear TT (2016) The Impact of altered T cell receptor—peptide-major histocompatibility complex interactions on antigen recognition and T cell function. Doctoral Disseration, Loyola University ChicagoGoogle Scholar
  2. 2.
    Spear TT, Nagato K, Nishimura MI (2016) Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunol Immunother 65:631–649. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL (2014) Engineered T cells for cancer therapy. Cancer Immunol Immunother 63:969–975. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Casucci M, Hawkins RE, Dotti G, Bondanza A (2015) Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 64:123–130. CrossRefGoogle Scholar
  5. 5.
    Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535–546. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Moore T, Wagner CR, Scurti GM et al (2018) Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol Immunother 67:311–325. CrossRefGoogle Scholar
  8. 8.
    Parkhurst MR, Yang JC, Langan RC et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620–626. CrossRefGoogle Scholar
  9. 9.
    Cameron BJ, Gerry AB, Dukes J et al (2013) Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Transl Med 5:197ra03. CrossRefGoogle Scholar
  10. 10.
    Linette GP, Stadtmauer EA, Maus MV et al (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122:863–871. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Morgan RA, Chinnasamy N, Abate-Daga D et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133–151. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Spear TT, Riley TP, Lyons GE et al (2016) Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 100:545–557. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tian S, Maile R, Collins EJ, Frelinger JA (2007) CD8 + T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol 179:2952–2960CrossRefGoogle Scholar
  14. 14.
    Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507–513Google Scholar
  15. 15.
    Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, Nishimura MI (1995) Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Can Res 55:748–752Google Scholar
  16. 16.
    Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI (2005) Simultaneous generation of CD8 + and CD4 + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Can Res 65:1570–1576. CrossRefGoogle Scholar
  17. 17.
    Stone JD, Chervin AS, Kranz DM (2009) T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126:165–176. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rees W, Bender J, Teague TK, Kedl RM, Crawford F, Marrack P, Kappler J (1999) An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 96:9781–9786CrossRefGoogle Scholar
  19. 19.
    Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI (2006) Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 43:973–981. CrossRefGoogle Scholar
  20. 20.
    Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177:6548–6559CrossRefGoogle Scholar
  21. 21.
    Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI (2003) CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 170:2582–2589CrossRefGoogle Scholar
  22. 22.
    Tsuji T, Yasukawa M, Matsuzaki J et al (2005) Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106:470–476. CrossRefGoogle Scholar
  23. 23.
    Eisen HN, Sykulev Y, Tsomides TJ (1996) Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv Protein Chem 49:1–56CrossRefGoogle Scholar
  24. 24.
    Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y (1998) Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 16:523–544. CrossRefGoogle Scholar
  25. 25.
    Kuball J, Schmitz FW, Voss RH et al (2005) Cooperation of human tumor-reactive CD4 + and CD8 + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22:117–129. CrossRefGoogle Scholar
  26. 26.
    Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA (2009) Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15:169–180. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173:1007–1015CrossRefGoogle Scholar
  28. 28.
    Holler PD, Holman PO, Shusta EV, O’Herrin S, Wittrup KD, Kranz DM (2000) In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA 97:5387–5392. CrossRefGoogle Scholar
  29. 29.
    Li Y, Moysey R, Molloy PE et al (2005) Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23:349–354. CrossRefGoogle Scholar
  30. 30.
    Zhao Y, Bennett AD, Zheng Z et al (2007) High-affinity TCRs generated by phage display provide CD4 + T cells with the ability to recognize and kill tumor cell lines. J Immunol 179:5845–5854CrossRefGoogle Scholar
  31. 31.
    Lamers CH, Willemsen R, van Elzakker P et al (2011) Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72–82. CrossRefGoogle Scholar
  32. 32.
    Combadiere B, Reis e Sousa C, Trageser C, Zheng LX, Kim CR, Lenardo MJ (1998) Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. Immunity 9:305–313CrossRefGoogle Scholar
  33. 33.
    Lenardo MJ, Boehme S, Chen L, Combadiere B, Fisher G, Freedman M, McFarland H, Pelfrey C, Zheng L (1995) Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Int Rev Immunol 13:115–134CrossRefGoogle Scholar
  34. 34.
    Riley TP, Baker BM (2018) The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics. Semin Cell Dev Biol 84:30–41. CrossRefGoogle Scholar
  35. 35.
    Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM (2004) Cutting edge: identification of hepatitis C virus-specific CD8 + T cells restricted by donor HLA alleles following liver transplantation. J Immunol 173:5355–5359CrossRefGoogle Scholar
  36. 36.
    Spear TT, Callender GG, Roszkowski JJ et al (2016) TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 65:293–304. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Spear TT, Wang Y, Foley KC et al (2017) Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. Cancer Immunol Immunother 66:1411–1424. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Spear TT, Wang Y, Smith TW Jr, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI (2018) Altered peptide ligands impact the diversity of polyfunctional phenotypes in T cell receptor gene-modified T cells. Mol Ther 26:996–1007. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lyons GE, Moore T, Brasic N, Li M, Roszkowski JJ, Nishimura MI (2006) Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Can Res 66:11455–11461. CrossRefGoogle Scholar
  40. 40.
    Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI (2009) Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother 58:719–728. CrossRefGoogle Scholar
  41. 41.
    Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI (2018) TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. J Leukoc Biol 103:973–983. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Foley KC, Spear TT, Murray DC, Nagato K, Garrett-Mayer E, Nishimura MI (2017) HCV T cell receptor chain modifications to enhance expression, pairing, and antigen recognition in T cells for adoptive transfer. Mol Ther Oncolytics 17:105–115. CrossRefGoogle Scholar
  43. 43.
    Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA (2000) A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12:251–261CrossRefGoogle Scholar
  44. 44.
    Kalergis AM, Nathenson SG (2000) Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 beta of an MHC class I-restricted TCR. J Immunol 165:280–285CrossRefGoogle Scholar
  45. 45.
    Thomson CT, Kalergis AM, Sacchettini JC, Nathenson SG (2001) A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCR-peptide/MHC class I interaction. J Immunol 166:3994–3997CrossRefGoogle Scholar
  46. 46.
    Wang Y, Singh NK, Spear TT et al (2017) How an alloreactive T-cell receptor achieves peptide and MHC specificity. Proc Natl Acad Sci USA. CrossRefGoogle Scholar
  47. 47.
    Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI (2010) Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6:e1001018. CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Riley TP, Hellman LM, Gee MH et al (2018) T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability. Nat Chem Biol 14:934–942. CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hellman LM, Foley KC, Singh NK et al (2018) Improving T cell receptor on-target specificity via structure-guided design. Mol Ther. CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Tsuchiya Y, Namiuchi Y, Wako H, Tsurui H (2018) A study of CDR3 loop dynamics reveals distinct mechanisms of peptide recognition by T-cell receptors exhibiting different levels of cross-reactivity. Immunology 153:466–478. CrossRefGoogle Scholar
  51. 51.
    Dustin ML, Bromley SK, Davis MM, Zhu C (2001) Identification of self through two-dimensional chemistry and synapses. Annu Rev Cell Dev Biol 17:133–157. CrossRefGoogle Scholar
  52. 52.
    Wu Y, Vendome J, Shapiro L, Ben-Shaul A, Honig B (2011) Transforming binding affinities from three dimensions to two with application to cadherin clustering. Nature 475:510–513. CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD, Zhu C (2010) The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 464:932–936. CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, Krogsgaard M (2014) 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Eur J Immunol 44:239–250. CrossRefGoogle Scholar
  55. 55.
    Liu B, Chen W, Evavold BD, Zhu C (2014) Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling. Cell 157:357–368. CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Pryshchep S, Zarnitsyna VI, Hong J, Evavold BD, Zhu C (2014) Accumulation of serial forces on TCR and CD8 frequently applied by agonist antigenic peptides embedded in MHC molecules triggers calcium in T cells. J Immunol 193:68–76. CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148–151. CrossRefGoogle Scholar
  58. 58.
    Haidar JN, Pierce B, Yu Y, Tong W, Li M, Weng Z (2009) Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins 74:948–960. CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M (2014) Specific increase in potency via structure-based design of a TCR. J Immunol 193:2587–2599. CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Pierce BG, Hellman LM, Hossain M, Singh NK, Vander Kooi CW, Weng Z, Baker BM (2014) Computational design of the affinity and specificity of a therapeutic T cell receptor. PLoS Comput Biol 10:e1003478. CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Zoete V, Irving M, Ferber M, Cuendet MA, Michielin O (2013) Structure-based, rational design of T cell receptors. Front Immunol 4:268. CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Chodon T, Comin-Anduix B, Chmielowski B et al (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457–2465. CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Gee MH, Han A, Lofgren SM et al (2018) Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell 172:549–63.e16. CrossRefGoogle Scholar
  64. 64.
    Riley TP, Ayres CM, Hellman LM et al (2016) A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces. Protein Eng Des Sel 29:595–606. CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Harris DT, Wang N, Riley TP, Anderson SD, Singh NK, Procko E, Baker BM, Kranz DM (2016) Deep mutational scans as a guide to engineering high affinity T cell receptor interactions with peptide-bound major histocompatibility complex. J Biol Chem 291:24566–24578. CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Border EC, Sanderson JP, Weissensteiner T, Gerry AB, Pumphrey NJ (2019) Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. Oncoimmunology 8:e1532759. CrossRefGoogle Scholar
  67. 67.
    Gee MH, Sibener LV, Birnbaum ME, Jude KM, Yang X, Fernandes RA, Mendoza JL, Glassman CR, Garcia KC (2018) Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro. Proc Natl Acad Sci USA 115:E7369–E7378. CrossRefGoogle Scholar
  68. 68.
    Audehm S, Glaser M, Pecoraro M et al (2019) Key features relevant to select antigens and TCR from the MHC-mismatched repertoire to treat cancer. Front Immunol 10:1485. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Timothy T. Spear
    • 1
    Email author
  • Brian D. Evavold
    • 2
  • Brian M. Baker
    • 3
  • Michael I. Nishimura
    • 1
  1. 1.Department of Surgery, Cardinal Bernardin Cancer CenterLoyola University ChicagoMaywoodUSA
  2. 2.Department of Pathology, Microbiology and ImmunologyUniversity of UtahSalt Lake CityUSA
  3. 3.Department of Chemistry and Biochemistry, Harper Cancer Research InstituteUniversity of Notre DameNotre DameUSA

Personalised recommendations